PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer ...

Delivering drugs to specific, hard-to-reach areas in the human body remains a challenge in drug development. Typically, drug molecules administered via pills or injections circulate randomly through ...

Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with ... phase 2 clinical studies for the treatment of type 2 diabetes. The gastrointestinal (GI) tract ...

Beyond Anticancer Therapeutics: Polymer–Drug Conjugates for the Treatment of Diseases other than Cancer In the last decade, the field of polymer–drug conjugates has expanded towards novel ...